Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Respiratory Syncytial Virus (RSV) G glycoprotein – central conserved domain (CCD) is a critical region of the viral attachment protein responsible for mediating host cell entry and modulating the immune response (UniProt: P03423). Unlike the highly variable mucin-like regions of the G protein, the CCD is highly conserved across RSV A and B strains, making it an attractive target for broad-spectrum therapeutics and vaccines (Anderson et al., 2021). A key feature of the CCD is a CX3C chemokine motif that mimics human fractalkine (CX3CL1), allowing the virus to bind to the CX3CR1 receptor on respiratory epithelial cells and immune cells (Tripp et al., 2001). This interaction not only facilitates infection but also disrupts normal leukocyte trafficking, contributing to the characteristic inflammation and airway obstruction seen in RSV-related bronchiolitis and pneumonia (Haynes et al., 2003). Therapeutic strategies targeting the CCD, such as monoclonal antibodies like 131-2G, aim to neutralize viral infectivity and mitigate the immunopathology associated with the CX3C-CX3CR1 interaction (Boyoglu-Barnum et al., 2015). Research suggests that targeting this domain may provide a safer alternative to whole-protein vaccines, which have historically been linked to enhanced respiratory disease.
Neutralization of viral attachment to host cells and inhibition of the CX3C-CX3CR1 interaction to prevent viral-induced immune modulation and inflammation (Tripp et al., 2001; Boyoglu-Barnum et al., 2015).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Respiratory syncytial virus G glycoprotein – central conserved domain (RSV G CCD) (RSV G CCD).